More than 90% of HHT patients have mutations in transforming growth factor β (TGFβ) family receptors, endoglin (ENG), or activin receptor-like kinase 1 (ALK1 or ACVLR1). This evidence concerns the gene ENG and hereditary hemorrhagic telangiectasia.